Matthew Volm is an Oncology physician affiliated with New York University. OpenAlex indexes 23 publications with 663 citations (h-index 10); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Chemotherapy in Treating Patients With Breast Cancer
Sponsor: NYU Langone Health
- Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer
Sponsor: NYU Langone Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
NIH funding
1 NIH research award on record, funded 1998–2002 per NIH RePORTER. The latest:
- LAB STUDY TO EVALUATE PACLITAXELS CELLULAR &MOLECULAR EFFECTS IN BREAST CANCER
New York University School of Medicine
FY2002M01RR000096 - RHUMAB HER2 IN RELAPSED BREAST CANCER PATIENTS W/ 2 PRIOR CHEMOTHERAPY REGIMENS
New York University School of Medicine
FY2002M01RR000096 - MULTIMODALITY THERAPY FOR LOCALLY ADVANCED BREAST CANCER
New York University School of Medicine
FY2002M01RR000096
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- RAD001-carboplatin combination in triple-negative metastatic breast cancer (TNMBC): A phase II trial.
Journal of Clinical Oncology
2013 - Phase II trial of RAD001 plus carboplatin in patients with triple-negative metastatic breast cancer.
Journal of Clinical Oncology
2012 - Efficacy of RAD001/carboplatin in triple-negative metastatic breast cancer: A phase II study.
Journal of Clinical Oncology
2012 - Standardizing quality breast cancer care throughout all New York university facilities.
Journal of Clinical Oncology
2012
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Alper, MD
New York University
William Rom, MD
New York University
Alec Megibow, MD
New York University
Jerry Shapiro, MD
New York University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”